Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:4595
Structure:
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carba
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9
108303-49-7
116002-70-1
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
99614-01-4
99614-02-5
AB00373674
BAS 00717177
BB_SC-1124
BPBio1_001118
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
D00456
DB00904
GR 38032
GR 38032X
GR-38032F
GR38032F
LS-172305
LS-51878
NCI60_022780
Ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
ONDANSETRON HYDROCHLORIDE
Ondansetron [USAN:INN:BAN]
Ondansetron, (+,-)-Isomer
Oprea1_435466
Oprea1_852372
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
SN-307
SPBio_002938
STK370548
TimTec1_001750
TL8006071
Zofran
ZOFRAN IN PLASTIC CONTAINER
Zofran ODT
Zofran ODT (TN)
ZOFRAN PRESERVATIVE FREE
Zophren
Zudan
ATC-Codes:
Side-Effects:
Side-EffectFrequency
headache0.15679899
drowsiness0.14006934
musculoskeletal pain0.10410519
fatigue0.094711296
malaise0.09471127
hypoxia0.08401517
diarrhea0.08056486
constipation0.073151514
dizziness0.06561335
bradycardia0.05787879
fever0.056153648
agitation0.049797885
anxiety0.049797878
urinary retention0.04165283
hypotension0.041169617
pruritus0.036746923
chest pain0.022582654
dysuria0.019424973
pain0.018705212
paresthesia0.014771492
bronchospasm0.009940465
tachycardia0
allergic reaction0
syncope0
ventricular extrasystoles0
stridor0
stevens - johnson syndrome0
supraventricular tachycardia0
tremor0
blindness0
shortness of breath0
dry mouth0
blurred vision0
second degree heart block0
hepatic failure0
urticaria0
myocardial ischemia0
shock0
seizures0
heart block0
grand mal0
toxic epidermal necrolysis0
edema0
abdominal pain0
dyskinesia0
atrial fibrillation0
arrhythmia0
angioedema0
angina pectoris0
rash0
flushing0
weakness0
palpitations0
myocardial infarction0
movement disorders0
mediastinal disorders0
liver disease0
hypokalemia0
hypersensitivity0
hiccup0
anaphylaxis0

Target

show target details
Uniprot ID:CP1A2_HUMAN
Synonyms:
CYPIA2
Cytochrome P450 1A2
P(3)450
P450 4
P450-P3
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2HI4
Structure:
2HI4

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----
----
----

References:

11996015
16946512
Effects of serotonin-3 receptor antagonists on cytochrome P450 activities in human liver microsomes.. Toshiro Niwa; Sachiko Yamamoto; Miho Saito; Naoto Kobayashi; Kaoru Ikeda; Yasuo Noda; Akira Takagi (2006) Biological & pharmaceutical bulletin display abstract
The effects of three serotonin-3 (5-HT(3)) receptor antagonists, azasetron, ondansetron, and ramosetron, on cytochrome P450 (CYP) 1A2-mediated 7-ethoxyresorufin O-deethylation, CYP2C9-mediated tolbutamide hydroxylation, CYP2C19-mediated S-mephenytoin 4'-hydroxylation, CYP2D6-mediated debrisoquine 4-hydroxylation, CYP2E1-mediated chlorzoxazone 6-hydroxylation, CYP3A4-mediated nifedipine oxidation, and CYP3A4-mediated testosterone 6beta-hydroxylation activities in human liver microsomes were compared. Azasetron and ramosetron at a concentration of 1 or 10 muM neither inhibited nor stimulated any of the metabolic activities. On the other hand, ondansetron competitively inhibited CYP1A2 and CYP2D6 activities, and the inhibition constants (K(i)) were 3.2 and 21.0 muM, respectively, which are much higher than the reported plasma concentrations after clinical intravenous or oral dosing. The free fractions of the three 5-HT(3) receptor antagonists in the incubation mixture estimated by ultracentrifugation were more than 68.6%. These results suggest that azasetron, ondansetron, and ramosetron do not cause clinically significant interactions with other drugs that are metabolized by CYPs via the inhibition of metabolism.
8591723